{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:19:58Z","timestamp":1785406798655,"version":"3.56.0"},"reference-count":23,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Acute myeloid leukemia (AML) presents differently across age groups, with unique challenges in the adolescent and young adult (AYA) populations. This study compares clinical characteristics and outcomes between AYA and adult AML patients in Qatar. We conducted a retrospective analysis of 151 AML patients treated at the National Center for Cancer Care and Research, Qatar, between 2017-2021. Patients were divided into AYA (15-39 years, n=73) and adults (\u226540 years, n=78) groups. Clinical characteristics, cytogenetic profiles, treatment approaches and survival outcomes were compared between groups. AYA patients (median age 30 years) showed distinct characteristics compared to adults (median age 53.9 years). AYA patients had lower platelet counts (62,900\/mm\u00b3 versus 96,500\/mm\u00b3, p=0.016) and higher blast percentages in peripheral blood and bone marrow (60% versus 40%, p=0.02). Core binding factor rearrangements were more common in AYA patients (32% versus 12%, p=0.03), while adult patients had more diploid karyotypes (55% versus 36%). AYA patients received more intensive therapy, with higher rates of FLAG-Ida salvage therapy (34% versus 15%) and allogeneic transplantation (32% versus 15%, p=0.01). While transplantation significantly improved survival in adults, its impact was less pronounced in AYA patients. Median overall survival was comparable between groups (23.14 versus 24.08 months, p=0.09). Our study reveals distinct biological and clinical characteristics between AYA and adult AML patients in Qatar. Despite receiving more intensive therapy, AYA patients showed comparable survival outcomes to adults, suggesting the need for age-specific treatment approaches. The differential impact of transplantation between age groups highlights the importance of personalized treatment strategies. These findings contribute to understanding age-specific differences in AML and may help optimize treatment approaches for both populations.<\/jats:p>","DOI":"10.46989\/001c.140933","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:46:06Z","timestamp":1750679166000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Treatment Outcomes of Acute Myeloid Leukemia in Adolescent and Young Adult versus Adult Patients: A Single-Center Experience in Qatar"],"prefix":"10.46989","volume":"7","author":[{"given":"Shehab","family":"Fareed","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Fadhl","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawraa","family":"Shwaylia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Mulikandathil","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Aldali","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena Sideeg","family":"Mudawi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Soliman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02zwb6n98","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feryal","family":"Abbas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02zwb6n98","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Yousef","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaplana","family":"Singh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02zwb6n98","id-type":"ROR","asserted-by":"publisher"}],"name":"Nursing Research Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group","volume":"27","author":"I. Tsukimoto","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial","volume":"155","author":"B. E. S. Gibson","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"ref3","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"G. Juliusson","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clml.2015.12.010","article-title":"Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)","volume":"16","author":"N. Pemmaraju","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5","volume":"17","author":"A. Trama","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"ref6","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1002\/cncr.28344","article-title":"Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials","volume":"119","author":"W. G. Woods","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"ref7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/10428194.2016.1231312","article-title":"Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base","volume":"58","author":"U. Durani","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"ref8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2017-12-778472","article-title":"Treatment strategies for adolescent and young adult patients with acute myeloid leukemia","volume":"132","author":"K. O\u2019Dwyer","year":"2018","journal-title":"Blood"},{"issue":"9","key":"ref9","doi-asserted-by":"publisher","first-page":"e27089","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"U. Creutzig","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2011.10.031","article-title":"Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia","volume":"18","author":"N. S. Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"ref11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"H. D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"30","author":"S. Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1634\/theoncologist.7-2-154","article-title":"Between parent and child: negotiating cancer treatment in adolescents","volume":"7","author":"R. T. Penson","year":"2002","journal-title":"Oncologist"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1365-2141.2002.03471.x","article-title":"Non-endocrine late complications of bone marrow transplantation in childhood: part II","volume":"118","author":"A. D. Leiper","year":"2002","journal-title":"Br J Haematol"},{"issue":"17","key":"ref15","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study","volume":"116","author":"C.-L. Sun","year":"2010","journal-title":"Blood"},{"issue":"9","key":"ref16","doi-asserted-by":"publisher","first-page":"e27089","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"U. Creutzig","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"ref17","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1080\/10428194.2022.2113527","article-title":"Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes","volume":"63","author":"C. Lalayanni","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107586","DOI":"10.1016\/j.leukres.2024.107586","article-title":"Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience","volume":"147","author":"R. Chen","year":"2024","journal-title":"Leukemia Research"},{"issue":"3\u20134","key":"ref19","first-page":"292","article-title":"Acute myeloid leukemia in adolescents and young adults: challenging aspects","volume":"132","author":"Y. Ofran","year":"2014","journal-title":"Acta Haematol"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"J. Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cncr.23220","article-title":"Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93\/98 and the adult trials AMLCG 92\/99 and AMLSG HD93\/98A","volume":"112","author":"U. Creutzig","year":"2008","journal-title":"Cancer"},{"issue":"27","key":"ref22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"A. S. Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004","volume":"122","author":"U. Creutzig","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/140933-clinical-characteristics-and-treatment-outcomes-of-acute-myeloid-leukemia-in-adolescent-and-young-adult-versus-adult-patients-a-single-center-experie","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:46:08Z","timestamp":1750679168000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/140933-clinical-characteristics-and-treatment-outcomes-of-acute-myeloid-leukemia-in-adolescent-and-young-adult-versus-adult-patients-a-single-center-experie"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.140933","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}